Article
Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer.
Oncotarget - 9 Feb 2016
French Juliet D, Johnatty Sharon E, Lu Yi, Beesley Jonathan, Gao Bo, Kalimutho Murugan, Henderson Michelle J, Russell Amanda J, Kar Siddhartha, Chen Xiaoqing, Hillman Kristine M, Kaufmann Susanne, Sivakumaran Haran, O'Reilly Martin, Wang Chen, Korbie Darren J, Lambrechts Diether, Despierre Evelyn, Van Nieuwenhuysen Els, Lambrechts Sandrina, Vergote Ignace, Karlan Beth, Lester Jenny, Orsulic Sandra, Walsh Christine, Fasching Peter A, Beckmann Matthias W, Ekici Arif B, Hein Alexander, Matsuo Keitaro, Hosono Satoyo, Pisterer Jacobus, Hillemanns Peter, Nakanishi Toru, Yatabe Yasushi, Goodman Marc T, Lurie Galina, Matsuno Rayna K, Thompson Pamela J, Pejovic Tanja, Bean Yukie, Heitz Florian, Harter Philipp, du Bois Andreas, Schwaab Ira, Hogdall Estrid, Kjaer Susanne K, Jensen Allan, Hogdall Claus, Lundvall Lene, Engelholm Svend Aage, Brown Bob, Flanagan James M, Metcalf Michelle D, Siddiqui Nadeem, Sellers Thomas, Fridley Brooke, Cunningham Julie, Schildkraut Joellen M, Iversen Ed, Weber Rachel Palmieri, Brennan Donal, Berchuck Andrew, Pharoah Paul, Harnett Paul, Norris Murray D, Haber Michelle, Goode Ellen L, Lee Jason S, Khanna Kum Kum, Meyer Kerstin B, Chenevix-Trench Georgia, deFazio Anna, Edwards Stacey L, MacGregor Stuart
Abstract excerpt
Women with epithelial ovarian cancer (EOC) are usually treated with platinum/taxane therapy after cytoreductive surgery but there is considerable inter-individual variation in response. To identify germline single-nucleotide polymorphisms (SNPs) that contribute to variations in individual responses to chemotherapy, we carried out a multi-phase genome-wide association study (GWAS) in 1,244 women diagnosed with...
Read the complete abstract on PubMed